Manoj Kumar Katual

Neurodegenerative disorders are conditions in which cells of the brain and/or spinal cord degenerate.  The brain and spinal cord are composed of neurons with different functions such as controlling skilled movements, processing sensory information, storage of information and making decisions. Cells of the brain and spinal cord do not usually regenerate, so damage to the nervous system can be devastating. Normally, the neurodegenerative process begins long before any symptoms appear. Neurodegenerative diseases result from deterioration of neurons or their myelin sheaths which over time will lead to dysfunction and disabilities. Neuro-degenerative diseases markedly affect the lives of millions and lead to a growing public health challenge with increased costs for individuals and society. The prevention and treatment of these neurodegenerative disorders represent a critical goal of medical research today. Most of these disorders increase with age. Today, there are 25 million suffering from dementia and it is generally believed that the prevalence will be 130 million demented persons by 2050. As the human outer skin proved it to be the largest organ of sense of body, that can be potentially used for the delivery of multiple therapy for the successful management of neurobehavioral disorders. Various novel approaches can be introduced for which further study is essential .The focus on this route has not been in limelight till yet. Transdermal drug delivery is helpful for topical and local action of the drug. . For the patients who have difficulties swallowing solids or liquids, a transdermal drug delivery may offer great advantages over conventional delivery methods. Drug delivery directly to the brain interstitium has recently been markedly enhanced through the rational design of polymer-based drug delivery system. After the oral administration of drugs, the huge variations were associated in plasma levels with regular gastintestinal symptoms including nausea, vomiting, diarrhea, constipation, anorexia, abdominal pain and abdominal distention. This drug administration route could therefore allow optimal therapeutic dose, potentially further improving the effectiveness of treatment. The transdermal delivery bypasses the first past metabolism and lesser side effects. This route may be explored for the delivery of nano-sized pharmaceuticals to the CNS as an alternate route.

The major objective of any dosage form development is to ensure the delivery of specific and reproducible amounts of pharmacologically active compounds to the body in the maximum amount possible. Today's most frequently used dosage forms are orally administered solids formulated such as tablets, capsules or powders. Timed-release products intend to improve delivery efficacy and/or effectiveness; for instance, the frequency of dosing can be reduced and, in certain cases, the actual daily dose can be reduced, offering the manufacturer a financial benefit. There have been many techniques developed for producing the variety of timed-release products. Ginger is a natural drug, which is used for nausea and vomiting, to treat bleeding disorders and rheumatism. In conventional dose is thrice a day, 8-10 gm which is not at all convenient for the patient. Increase the patient compliance is also a great challenge which is continuously improving by the novel drug delivery system. The main objective of the present work is to design Ginger root extract powder (5%w/w of 6-gingerol) timed release dosage form of the drug with the help of a novel clear transparent veggie capsule shell of ‘0’ size made up of cellulose and natural substance. The objective in formulating a sustained release dosage form is to be able to provide a similar blood plasma level pattern for up to desired hrs (12hrs) after oral administration of the drug. The formulation, optimization, destructive quantification parameters and in-vitro studies of the drug have focused in this research article. The presented work sought a futuristic research for the benefit of the patients.

The aim of present investigation was to develop a simple UV-visible spectrophotometric method for the determination of Ibuprofen (IBF) in its pure form and marketed formulations and to validate the developed method. Ibuprofen was estimated at UV maxima of 222.8 nm in pH 7.2 phosphate buffer using UV-Visible double beam spectrophotometer. Following the guidelines of International Conference on Harmonization (ICH), the analytical parameters like linearity, precision, and accuracy were studied. The obtained results of analysis were validated statistically and by performing recovery studies to confirm the accuracy of the proposed method. In the developed method, linearity over the concentration range of 2-20 µg/ml of IBF was observed and was found in agreement of Beer’s law. The linear regression was found to be 0.999. The precision (intra-day & inter-day) of method was found within limits (RSD < 2%). The sensitivity of the method was assessed by determining limit of detection and limit of quantification. It could be concluded from the results obtained that the method for estimation of IBF in pure form and in marketed tablets is simple, rapid, accurate, precise and economical and can be used, successfully, in the quality control of pharmaceutical formulations and routine laboratory analysis.